COVID-19 Videocast Series – Episode 3: Executive Compensation Considerations (Video)

F
Fenwick

Contributor

Fenwick logo
Fenwick provides comprehensive legal services to leading technology and life sciences companies — at every stage of their lifecycle — and the investors that partner with them. For more than four decades, Fenwick has helped some of the world's most recognized companies become and remain market leaders. Visit fenwick.com to learn more.
In this episode, the Fenwick team addresses complex issues facing public company boards and compensation committees as companies adapt to the economic impact of COVID-19,...
United States Corporate/Commercial Law
To print this article, all you need is to be registered or login on Mondaq.com.

Conversations from Our Public Company Virtual Situation Room, Episode 3

In this episode, the Fenwick team addresses complex issues facing public company boards and compensation committees as companies adapt to the economic impact of COVID-19, as well as considerations for executive compensation actions, including timing, adjustments of performance targets, exercise of discretion, usage of equity, repricings, expiring equity awards, salary adjustments and related matters.

Go directly to the topic(s) of most interest to you:

Big picture – 1:36
Go forward performance metrics and adjusting existing metrics – 4:45
Executive salary reductions – 10:01
Re-pricing – 17:32
Expiring equity grants – 19:00
409A considerations – 20:51

Fenwick's periodic videocasts discuss key topics that you, your company, board, board committees, and public reporting and compliance teams need to focus on during the COVID-19 pandemic. The Fenwick team will share best practices and steps that we are seeing our tech and life sciences clients take during these uncertain times.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More